UK

Life Sciences M&A in a holding pattern

Matthew Appleton

Continued uncertainty surrounding President Trump’s proposed tax reforms has slowed activity in the Life Sciences sector, with deal values holding well below the record levels seen in previous years. If Trump’s promised corporate tax cut materialises, big U.S. players may be encouraged to repatriate (and spend) the huge amounts of cash currently held offshore.  But Read More

European and UK medical device industry bodies urge post-Brexit regulatory alignment

William Palmer

In a joint letter to the negotiators representing the UK and EU, medical device and in vitro diagnostic industry trade groups have urged both parties to ensure full regulatory implementation in their sector following “Brexit”, in March 2019.  The trade groups represented are MedTech Europe (MedTech), the Association of British Healthcare Industries (ABHI) and the Read More

The definition of “product” in the SPC Regulation: (Part 1 of 2) What’s in a name?

Nicola Dagg

Anyone familiar with supplementary protection certificate (SPC) law will know the importance of the definition of “product” for SPC purposes. “Product” is defined within art.1(b) of Regulation (EC) No 469/2009 (the SPC Regulation) and plays a central role in the interpretation of that Regulation, in particular as regards the conditions for obtaining an SPC set Read More

UK position on Continuity in the Availability of Goods for the EU and the UK set out as Brexit negotiations continue

Erin Currie

A number of position papers have recently been published as negotiations continue on the UK’s withdrawal from the EU.  One such position paper from the UK is the Continuity in the availability of goods for the EU and the UK, published on 21 August 2017, which sets out proposals that will be applicable to the Read More

UK Life Sciences companies need full-cycle support to grow

Matthew Appleton

Now that the dust is settling after the publication of the UK’s “Life Sciences: industrial strategy”, it seems a good time to focus on one of the report’s key themes – growth. The report rightly notes that despite the UK having a strong track record in Life Sciences companies emerging, very few of those have Read More